UNASSIGNED: 5087 Background: There is no current standard of salvage chemotherapy in recurrent @entity43 . @entity901 is an effective third generation @entity902 compound which has no complete cross-resistance with @entity3003 or @entity900 in @entity43 . The purpose of our study was to assess efficacy and tolerability of combination of @entity901 and @entity632 in second-line chemotherapy of @entity43 . METHODS: In case of disease progression following first-line chemotherapy pts received second-line chemotherapy with @entity901 130 mg/m(2) and @entity632 50 mg/m(2) q3w. @entity1054 ( @entity1054 ) was chosen as the primary end-point. Three investigator centers participated in the study. RESULTS: Totally 29 pts were included in this study. @entity5 were @entity902 -sensitive (PFI>12 m) in 5 (17.2%), partially @entity902 -sensitive (PFI>6 m) in 12 (41.4%), @entity902 -resistant (PFI<6 m) in 11 (38.0%) cases, in 1 (3.4%) case sensitivity of @entity5 to @entity902 was not known. Objective response rate was 55.1% (24.1% complete remissions and 31.0% partial remissions). The median @entity1054 was 10.7 m. With the median f.-up of 14.8 m the median overall survival was not reached. 1-year overall survival was 89%. There were no statistically significant differences in response rate and @entity1054 between @entity902 -sensitive and @entity902 -resistant @entity5 (p>0.05). The median number of cycles was 5 (range 2-6). @entity137 grade 3-4 per cycle included @entity1398 14.6%, @entity1398 0.7%, @entity882 5.1%. @entity16 grade 1-2 and 3 was observed in 8 (27.6%) and 2 (1.4%) cases respectively. There were 5 cases of @entity901 dose reductions and 10 cases of @entity632 dose reductions; 10 cycles of chemotherapy were delayed due to @entity137 . CONCLUSIONS: The combination of @entity901 and @entity632 showed promising efficacy in either @entity902 -sensitive or @entity902 -resistant recurrent @entity43 . Tolerability of this regimen was acceptable.

The phase II study of efficacy and safety of @entity901 with @entity632 in recurrent @entity43 ( XXXX ).

@entity43 :: ('MESH:D010051', 'Disease') :: ['OC'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin', 'Oxaliplatin'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors', 'cancers'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Sensory neuropathy'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'Time to progression'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity43 :: (MESH:D010051,Disease) :: ['OC']
